Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multicentre phase I/II trial to investigate the efficacy, biological activity, safety and tolerability of IPH 1101 and low dose interleukin-2 in combination with rituximab [Mabthera/Rituxan] in patients with follicular non-Hodgkin's lymphoma relapsing after at least one prior rituximab-containing course of treatment.

Next Previous
X
Search
Trial Profile

A multicentre phase I/II trial to investigate the efficacy, biological activity, safety and tolerability of IPH 1101 and low dose interleukin-2 in combination with rituximab [Mabthera/Rituxan] in patients with follicular non-Hodgkin's lymphoma relapsing after at least one prior rituximab-containing course of treatment.

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 02 Jun 2011

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs IPH 1101 (Primary) ; Aldesleukin; Rituximab
  • Indications Follicular lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Innate Pharma

    • Most Recent Events

    • 14 Jun 2010 Status changed from recruiting to active, no longer recruiting.
    • 14 Jun 2010 Final data of this trial has been presented at the Annual European Hematology Association (EHA) Meeting 2010, according to an Innate Pharma media release.
    • 03 Jun 2010 Final data will be the subject of an oral presentation by Pr Jean-Francois Rossi at the Annual European Hematology Association (EHA) Meeting 2010, according to an Innate Pharma media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top